Review



fancd2  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech fancd2
    Fancd2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody/pmc12936848-59-0-2
    Average 93 stars, based on 20 article reviews
    fancd2 - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Control:

    Article Title: The Compromised Fanconi Anemia Pathway in Prelamin A-Expressing Cells Contributes to Replication Stress-Induced Genomic Instability.
    Article Snippet: .. Antibodies and Reagents: Anti-lamin A/C (Proteintech, 10298-1-AP), anti-lamin A/C (Santa Cruz, sc-376248), anti-lamin B1 (Proteintech, 12987-1-AP), anti-β-actin (ABclonal, AC026), anti-β-tubulin (ABclonal, AC021), anti-vinculin (Proteintech, 26520-1-AP), anti-H2AX-pS139 (Santa Cruz, sc-517348), anti-p53 (Proteintech, 60283-2-Ig), anti-p21 (Proteintech, 10355-1-AP), anti-H3 (Proteintech, 17168-1-AP), anti-E2F1 (Proteintech, 66515-1-Ig), anti-E2F1 (ABclonal, A19579), anti-E2F4 (Proteintech, 10923-1-AP), anti-RB (ABclonal, A3618), anti-p130 (ABclonal, A13649), anti-p-RB (S807/811) (Proteintech, 30376-1-AP), anti-FANCD2 (Proteintech, 28619-1-AP), anti-FANCD2 (Novus biologicals, NB100-182), antiFANCB (ZEN BIO, 384 281), anti-FANCI (Proteintech, 67304-1-Ig), antiRAD51 (Proteintech, 14961-1-AP), anti-53BP1 (ABclonal, A5757), antiRPA2 (Santa Cruz, sc-56770), rabbit control IgG (ABclonal, AC005) and mouse control IgG (ABclonal, AC011) were used. .. LPV (MCE, HY-14588), FTI-277 (MCE, HY-15872A), HU (Sigma– Aldrich, H8627), APH (Glpbio, GC10867), colcemid (Glpbio, GC40664), Nutlin-3A (MCE, HY-10029), and mirin (MCE, HY-117693) were used.

    Article Title: The Compromised Fanconi Anemia Pathway in Prelamin A‐Expressing Cells Contributes to Replication Stress‐Induced Genomic Instability
    Article Snippet: .. Anti‐lamin A/C (Proteintech, 10298‐1‐AP), anti‐lamin A/C (Santa Cruz, sc‐376248), anti‐lamin B1 (Proteintech, 12987‐1‐AP), anti‐β‐actin (ABclonal, AC026), anti‐β‐tubulin (ABclonal, AC021), anti‐vinculin (Proteintech, 26520‐1‐AP), anti‐H2AX‐pS139 (Santa Cruz, sc‐517348), anti‐p53 (Proteintech, 60283‐2‐Ig), anti‐p21 (Proteintech, 10355‐1‐AP), anti‐H3 (Proteintech, 17168‐1‐AP), anti‐E2F1 (Proteintech, 66515‐1‐Ig), anti‐E2F1 (ABclonal, A19579), anti‐E2F4 (Proteintech, 10923‐1‐AP), anti‐RB (ABclonal, A3618), anti‐p130 (ABclonal, A13649), anti‐p‐RB (S807/811) (Proteintech, 30376‐1‐AP), anti‐FANCD2 (Proteintech, 28619‐1‐AP), anti‐FANCD2 (Novus biologicals, NB100‐182), anti‐FANCB (ZEN BIO, 384 281), anti‐FANCI (Proteintech, 67304‐1‐Ig), anti‐RAD51 (Proteintech, 14961‐1‐AP), anti‐53BP1 (ABclonal, A5757), anti‐RPA2 (Santa Cruz, sc‐56770), rabbit control IgG (ABclonal, AC005) and mouse control IgG (ABclonal, AC011) were used. .. LPV (MCE, HY‐14588), FTI‐277 (MCE, HY‐15872A), HU (Sigma–Aldrich, H8627), APH (Glpbio, GC10867), colcemid (Glpbio, GC40664), Nutlin‐3A (MCE, HY‐10029), and mirin (MCE, HY‐117693) were used.

    other:

    Article Title: Celastrol Induces DNA Damage and Cell Death in BCR-ABL T315I-mutant CML by Targeting YY1 and HMCES
    Article Snippet: Background: Chronic myeloid leukemia (CML) is driven primarily by the constitutively active BCR-ABL fusion oncoprotein.. Although the development of tyrosine kinase inhibitors has markedly improved the prognosis of CML patients, it remains a significant challenge to overcome drug-resistant mutations, such as the T315I mutation of BCR-ABL, and achieve treatment-free remission in the clinic.

    Article Title: USP5-mediated CD73 deubiquitination drives osimertinib resistance via PI3K/AKT and glycolysis activation in LUAD
    Article Snippet: FANCD2 , Proteintech , Cat# 28619-1-AP; RRID: AB_2881182.

    Ubiquitin Proteomics:

    Article Title: USP5-Mediated CD73 Deubiquitination Drives Osimertinib Resistance via PI3K/AKT and Glycolysis Activation in LUAD
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies USP5 Proteintech Cat# 10473-1-AP; RRID:AB_2272754 CD73 Abcam Cat# ab317462; RRID:AB_3739483 TRIM28/KAP1 Proteintech Cat# 66630-1-Ig; RRID:AB_2732886 GAPDH ABclonal Cat# A19056; RRID:AB_2862549 β-Actin Proteintech Cat# 66009-1-Ig; RRID:AB_2687938 Flag/DYKDDDDK tag Proteintech Cat# 20543-1-AP; RRID:AB_11232216 His-Tag Proteintech Cat# 66005-1-Ig; RRID:AB_11232599 Ubiquitin Proteintech Cat# 10201-2-AP; RRID:AB_671515 Anti-Ubiquitin(linkage-specific K48) Abcam Cat# ab140601; RRID:AB_2783797 Anti-Ubiquitin(linkage-specific K63) Abcam Cat# ab179434; RRID:AB_2895239 VeriBlot for IP Detection(HRP) Abcam Cat# ab131366; RRID:AB_2892718 E-cadherin Proteintech Cat# 20874-1-AP; RRID:AB_10697811 N-cadherin Proteintech Cat# 22018-1-AP; RRID:AB_2813891 Vimentin Proteintech Cat# 10366-1-AP; RRID:AB_2273020 Caspase 3 Abways Technology CY5051; RRID:AB_3739491 Cleaved-caspase 3 Abcam Cat# ab32042; RRID:AB_725947 Caspase 9 Abways Technology CY5782; RRID:AB_3739492 Cleaved-caspase 9 Abways Technology CY5682; RRID:AB_3739493 HIF-1α Proteintech Cat# 20960-1-AP; RRID:AB_10732601 c-Myc Proteintech Cat# 10828-1-AP; RRID:AB_2148585 p-EGFR(Y1197) Abways Technology CY5614; RRID:AB_3739494 GLUT1 Proteintech Cat# 21829-1-AP; RRID:AB_10837075 Hexokinase II (HK2) Zen-Bioscience Cat# R24552; RRID:AB_3719314 PFKM Proteintech Cat# 55028-1-AP; RRID:AB_10858390 PKM2 Proteintech Cat# 15822-1-AP; RRID:AB_1851537 GPI Proteintech Cat# 15171-1-AP; RRID:AB_2263537 ENO1 Proteintech Cat# 11204-1-AP; RRID:AB_2099064 PGK1 Proteintech Cat# 17811-1-AP; RRID:AB_2161218 LDHA Proteintech Cat# 19987-1-AP; RRID:AB_10646429 MCT4 Proteintech Cat# 22787-1-AP; RRID:AB_11182479 PKM Abways Technology Cat# CY5764; RRID:AB_3675888 TPI1 Proteintech Cat# 10713-1-AP; RRID:AB_2207716 Bax Proteintech Cat# 50599-2-Ig; RRID:AB_2061561 Bcl-2 Proteintech Cat# 26593-1-AP; RRID:AB_2818996 PARP1 Proteintech Cat# 13371-1-AP; RRID:AB_2160459 Cleaved-PARP 1 (D214) Abways Technology CY5035; RRID:AB_3739495 FANCD2 Proteintech Cat# 28619-1-AP; RRID:AB_2881182 RAD51 Proteintech Cat# 14961-1-AP; RRID:AB_2177083 XRCC1 Proteintech Cat# 21468-1-AP; RRID:AB_2878865 CHK1 Proteintech Cat# 60277-1-Ig; RRID:AB_2881396 53BP1 Abways Technology CY6831; RRID:AB_3739497 γ-H2AX Proteintech Cat# 68888-1-Ig; RRID:AB_3670446 PCNA Proteintech Cat# 10205-2-AP; RRID:AB_2160330 (Continued on next page) iScience 29, 114916, March 20, 2026 e1 ..

    Western Blot:

    Article Title: Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors
    Article Snippet: Anti-SmD2 antibody rabbit antibody (198296, 1:1000 for Immunoblot and I:200 for IHC) and anti-gamma H2A.X (phospho S139) rabbit antibody (81299, 1:1000 for Immunoblot, 1:500 for immunofluorescence, and I:200 for IHC) are from Abcam. .. Anti-FANCA rabbit antibody (11975-1-AP, 1:800 for Immunoblot and 1:50 for IHC) and anti-FANCD2 rabbit antibody (28619-1-AP, 1:800 for Immunoblot and 1:50 for IHC) are from Proteintech. ..

    Immunohistochemistry:

    Article Title: Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors
    Article Snippet: Anti-SmD2 antibody rabbit antibody (198296, 1:1000 for Immunoblot and I:200 for IHC) and anti-gamma H2A.X (phospho S139) rabbit antibody (81299, 1:1000 for Immunoblot, 1:500 for immunofluorescence, and I:200 for IHC) are from Abcam. .. Anti-FANCA rabbit antibody (11975-1-AP, 1:800 for Immunoblot and 1:50 for IHC) and anti-FANCD2 rabbit antibody (28619-1-AP, 1:800 for Immunoblot and 1:50 for IHC) are from Proteintech. ..



    Similar Products

    95
    Novus Biologicals fancd2
    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
    Fancd2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody+-+BSA+Free/pmc13650023-29-113-115
    Average 95 stars, based on 1 article reviews
    fancd2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    OriGene sc305556
    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
    Sc305556, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+(NM_033084)+Human+Untagged+Clone/pmc13641737-211-20-21
    Average 94 stars, based on 1 article reviews
    sc305556 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    85
    Thermo Fisher gene exp fancd2 hs00276992 m1
    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
    Gene Exp Fancd2 Hs00276992 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/Gene+Exp%2E+FANCD2%2C+Hs00276992_m1/pm41922714-196-15-33
    Average 85 stars, based on 1 article reviews
    gene exp fancd2 hs00276992 m1 - by Bioz Stars, 2026-11
    85/100 stars
      Buy from Supplier

    93
    Proteintech fancd2
    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
    Fancd2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody/pmc12936848-59-0-2
    Average 93 stars, based on 1 article reviews
    fancd2 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology rad51
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, <t>RAD51,</t> and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Rad51, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody/pmc12964014-41-25-26
    Average 94 stars, based on 1 article reviews
    rad51 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology fancd2
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, <t>FANCD2,</t> RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Fancd2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody/pmc12964014-41-20-21
    Average 94 stars, based on 1 article reviews
    fancd2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti fancj
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, <t>FANCD2,</t> RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Anti Fancj, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Rabbit+mAb/pmc13006209-83-43-44
    Average 94 stars, based on 1 article reviews
    anti fancj - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti fancd2
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, <t>FANCD2,</t> RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Anti Fancd2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Rabbit+mAb/pmc13006209-83-38-39
    Average 94 stars, based on 1 article reviews
    anti fancd2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Novus Biologicals anti fancd2
    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, <t>FANCD2,</t> RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.
    Anti Fancd2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fancd2/FANCD2+Antibody+(FI-17)/us12558369-285-24-25
    Average 94 stars, based on 1 article reviews
    anti fancd2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and FANCD2) and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.

    Journal: Advanced Science

    Article Title: Alkylating Agent–Induced FANCL Impairment Damages Pulmonary Arterial, Venous, and Microvascular Endothelial Cells and Predisposes to PAH/PVOD

    doi: 10.1002/advs.78081

    Figure Lengend Snippet: MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and FANCD2) and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.

    Article Snippet: Primary antibodies for fibronectin (FN, #15613‐I‐AP, Proteintech, Rosemont, IL, USA), Twist (ab50887, Abcam, Cambridge, MA, USA), Vimentin (#5741, Cell Signaling Technology, Danvers, MA, USA), Snail (#ab53519, Abcam, Cambridge, MA, USA), ZO‐1 (21773‐1‐AP, proteintech, Wuhan, China), VEGFR2 (9698, CST, Boston, USA), Slug (YM8357, Immunoway, California, USA), proliferating cell nuclear antigen (PCNA, ab29, Abcam, Cambridge, MA, USA), CD31 (AF3628, R&D Systems, Minneapolis, MN, USA), Cleaved caspase3 (#9664, Cell Signaling Technology, Danvers, MA, USA), Bax (#2772S, Cell Signaling Technology, Danvers, MA, USA), B‐cell lymphoma/leukemia 2 (Bcl‐2, 13–8800, Thermo Fisher Scientific, Rockford, IL, USA), γ‐H2AX (#05‐635, EMD Millipore/Merck, USA), α‐smooth muscle actin (α‐SMA, ab124964 and ab7817, Abcam, Cambridge, MA, USA), FANCL (LS‐C807939, LifeSpan BioSciences, Seattle, WA, USA), FANCD2 (NB100‐182, Novus Biologicals, USA), general control nonderepressible 2 (GCN2, #46041, Cell Signaling Technology, Danvers, MA, USA), and β‐actin (66009‐1‐Ig, Proteintech, Rosemont, IL, USA) were used for immunoblotting, immunofluorescence (IF), and immunohistochemistry (IHC) staining.

    Techniques: Western Blot, Expressing, Tissue, Immunohistochemical staining, Staining, Marker, Immunofluorescence, Analysis, Fluorescence, MANN-WHITNEY, Control

    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.

    Journal: Blood Advances

    Article Title: Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma ∗

    doi: 10.1182/bloodadvances.2025016765

    Figure Lengend Snippet: Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.

    Article Snippet: Western blotting (WB) was performed to evaluate the expression levels of total protein and phospho-specific isoforms using the following antibodies: FANCD2 (Santa Cruz Biotechnology, sc-20022), RAD51 (Santa Cruz Biotechnology, sc-398587), PBEF (Santa Cruz Biotechnology, sc-166946), cleaved Caspase3 (Cell Signaling Technology, 9664s), PARP (Cell Signaling Technology, 9532s), cleaved PARP (Cell Signaling Technology, 5625s), γ-H2AX (Ser139; Cell Signaling Technology, 9718s), p-CHK1 (Ser345; Cell Signaling Technology, 2341s), p53 (Cell Signaling Technology, 2527s), p-ATR (Ser428; Cell Signaling Technology, 2853s), p-ATM (Ser1981; Cell Signaling Technology, 4526s), and p-CHK2 (Thr68; Cell Signaling Technology, 2197s).

    Techniques: Inhibition, In Vivo, Injection, Radio Immunoprecipitation, Control

    Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.

    Journal: Blood Advances

    Article Title: Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma ∗

    doi: 10.1182/bloodadvances.2025016765

    Figure Lengend Snippet: Inhibition of NAMPT function via KPT-9274 inhibits tumor growth in vivo. (A) NOG mice were injected subcutaneously with Mino cells. After detection of the tumor, the mice were randomized and treated orally with either KPT-9274 or the vehicle for 5 consecutive days per week for 3 weeks. Tumor volume was evaluated via caliper measurement. Differences between the 2 groups were evaluated using the standard t test. (B) Tumor cells collected from mice were lysed in radio-immunoprecipitation assay buffer, and the whole-cell lysate was subjected to WB analysis and probed with antibodies against Cl-PARP, FANCD2, RAD51, and γ-H2AX. GAPDH was used as the loading control. ns > .05; ∗∗ P ≤ .01; ∗∗∗ P ≤ .001; ∗∗∗∗ P ≤ .0001.

    Article Snippet: Western blotting (WB) was performed to evaluate the expression levels of total protein and phospho-specific isoforms using the following antibodies: FANCD2 (Santa Cruz Biotechnology, sc-20022), RAD51 (Santa Cruz Biotechnology, sc-398587), PBEF (Santa Cruz Biotechnology, sc-166946), cleaved Caspase3 (Cell Signaling Technology, 9664s), PARP (Cell Signaling Technology, 9532s), cleaved PARP (Cell Signaling Technology, 5625s), γ-H2AX (Ser139; Cell Signaling Technology, 9718s), p-CHK1 (Ser345; Cell Signaling Technology, 2341s), p53 (Cell Signaling Technology, 2527s), p-ATR (Ser428; Cell Signaling Technology, 2853s), p-ATM (Ser1981; Cell Signaling Technology, 4526s), and p-CHK2 (Thr68; Cell Signaling Technology, 2197s).

    Techniques: Inhibition, In Vivo, Injection, Radio Immunoprecipitation, Control